UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    29

    Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

    Read More Share:linkedin| twitter| email

    Nov

    27

    UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

    Read More Share:linkedin| twitter| email

    Nov

    17

    Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

    Read More Share:linkedin| twitter| email

    Nov

    14

    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Nov

    11

    Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

    Read More Share:linkedin| twitter| email

    Nov

    10

    UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

    Read More Share:linkedin| twitter| email

    Nov

    09

    Advancing Rheumatic Disease Treatment

    Read More Share:linkedin| twitter| email

    Nov

    06

    Partnering with Caregivers to Advance the Ecosystem of Care for Rare Epilepsies

    Read More Share:linkedin| twitter| email

    Nov

    02

    Supporting Sustainable Communities and Inspiring Science

    Read More Share:linkedin| twitter| email

    Nov

    01

    UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)